針對骨密度醫療食品
Sōlaria Biō 推出名為 Bondia™ 的產品
Sōlaria Biō 這項突破性產品——命名為 Bondia™——被歸類為一款醫療食品，用於協助管理停經後女性骨質密度流失的問題。
Bondia™ 配方，運用腸道—骨骼軸理論運作原理，旨在減緩導致骨質退化的發炎過程。這家公司引用一項刊登於同行評審期刊的臨床研究，作為其功效聲稱的依據。此研究追蹤了 286 位每日服用 Bondia™ 的停經後女性，發現對於患有骨質減少症或身體質量指數（BMI）達到或超過 30 的女性，這款醫療食品「相比安慰劑，能顯著減緩骨質流失速度」。
Sōlaria Biō 的 Bondia™，代表著一個全新的介入類別，有別於藥物或標準膳食補充劑。這款醫療食品被定位為一個主動出擊的方案，用以應對一項通常在傳統篩查開始前，便已悄然出現的健康問題。
英文原文
Sōlaria Biō's breakthrough product — which is dubbed Bondia™ — is classified as a medical food intended for the dietary management of bone density loss in postmenopausal women.
The Bondia™ formulation operates on the principle of the gut-bone axis. It aims to mitigate inflammatory processes that contribute to bone deterioration. The company cites a clinical study, which was published in a peer-reviewed journal, to support its claims. The study followed 286 postmenopausal women who were taking Bondia™ daily. It found that the medical food "significantly slowed bone loss compared to placebo in women with osteopenia or a BMI greater than/equal to 30."
Sōlaria Biō's Bondia™ represents a new category of intervention, one that is distinct from pharmaceutical drugs or standard dietary supplements. The medical food is positioned as a proactive option for a health issue that typically manifests before conventional screening begins.
- 來源
- Trend Hunter
- 發布
- 2025-11-17
- 品類
- Boomers
- 出處
- biospace, insider.fitt.co